Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | GGT1 | P19440 | 2/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935516 | 0.81 | — | — | |
| SCHEMBL2923837 | 0.81 | — | — | |
| SCHEMBL600881 | 0.80 | SLC7A5 (0.68) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 | |
| SCHEMBL627720 | 0.80 | LMNA (0.50) | SLC7A5 | |
| SCHEMBL9545322 | 0.80 | SLC7A5 (0.68) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 | |
| SCHEMBL29024969 | 0.80 | SLC7A5 (0.68) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 | |
| Hydrochloric Acid SCHEMBL8892666 | 0.77 | SLC7A5 (0.65) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 | |
| SCHEMBL31425228 | 0.77 | — | — | |
| SCHEMBL2385220 | 0.77 | — | — | |
| SCHEMBL3507890 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9375497-B2 | [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamine, derivatives thereof and use thereof and processes for their preparation | PIRAMAL IMAGING SA (CH) | 2016-06-28 | — | — | US | disclosed |
| US-9308282-B2 | [F-18]-labelled L-glutamic acid and L-glutamine derivatives (I), their use and processes for their preparation | PIRAMAL IMAGING SA (CH) | 2016-04-12 | — | — | US | disclosed |
| US-20140301948-A1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140154183-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | LIFE MOLECULAR IMAGING SA (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20110165076-A1 | NOVEL [F-18]- LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), USE THEREOF AND METHOD FOR THEIR PRODUCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110104057-A1 | Novel [F-18]-labelled L-glutamic acid and L-glutamine derivatives (II), their use and processes for their preparation | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20100290991-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100217011-A1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-26 | — | — | US | disclosed |
| CN-1052144-A | The Compounds and methods for of diagnosis and treatment cancer | AUSTRALIAN COMMERCIAL RESEARCH (AU) | 1991-06-12 | — | — | CN | disclosed |
| US-4202976-A | Selenium-75 labelled derivatives of folates | BAYLY RUSSELL J (GB) | 1980-05-13 | — | — | US | disclosed |
| US-4115065-A | COMPETITIVE RADIOASSAY | THE RADIOCHEMICAL CENTRE LIMITED (GB) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217011-A1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | GLUL, GFPT1, QPCT | SLC7A5 59/4885SLC1A1 13/4885SLC1A3 12/4885 |
| US-20100290991-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | GLUL, QPCT, SLC1A2 | SLC7A5 57/4885SLC1A1 12/4885SLC1A3 8/4885 |
| US-20140301948-A1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | GLUL, GFPT1, QPCT | SLC7A5 59/4885SLC1A1 13/4885SLC1A3 12/4885 |
| US-20140154183-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | GLUL, QPCT, SLC1A2 | SLC7A5 57/4885SLC1A1 12/4885SLC1A3 8/4885 |
| US-20110165076-A1 | NOVEL [F-18]- LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), USE THEREOF AND METHOD FOR THEIR PRODUCTION | GLUL, QPCT, GFPT1 | SLC7A5 61/4885SLC1A1 15/4885SLC1A3 14/4885 |
| US-20110104057-A1 | Novel [F-18]-labelled L-glutamic acid and L-glutamine derivatives (II), their use and processes for their preparation | GLUL, QPCT, SLC1A2 | SLC7A5 56/4885SLC1A1 11/4885SLC1A3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.